Technology & Science
FDA Reverses Feb-10 Refusal, Accepts Moderna mRNA-1010 Flu Vaccine for Review
Eight days after issuing a refusal-to-file letter, the FDA on 18 Feb 2026 agreed to review Moderna’s amended BLA for its mRNA-1010 seasonal flu shot, setting an Aug 5 decision deadline and split approval pathways for adults 50-64 (full) and 65+ (accelerated).
Focusing Facts
- Original Refusal-to-File letter signed by vaccine chief Dr. Vinay Prasad on 10 Feb 2026 cited lack of a high-dose comparator for adults 65+; Moderna’s amended filing was accepted on 18 Feb 2026 after a Type A meeting.
- The accepted filing carries a Prescription Drug User Fee Act (PDUFA) target date of 5 Aug 2026, aiming for U.S. market launch in the 2026-27 flu season for roughly 115 million Americans aged 50 and over.
- HHS Secretary Robert F. Kennedy Jr. had canceled 22 government mRNA respiratory-virus contracts worth $500 million on 5 Aug 2025, underscoring official skepticism toward the platform.
Context
Regulatory flip-flops are not new: in 1955 the FDA halted Salk polio vaccine lots after the Cutter Incident, only to resume licensure weeks later once safety criteria tightened. Today’s mRNA-1010 reversal echoes that tension between rapid innovation and institutional caution. The episode sits at the crossroads of two long-term arcs—the century-long expansion of adult immunization (from the first flu shot in 1945 to the high-dose Fluzone in 2009) and the post-COVID politicization of mRNA technology. By publicly over-ruling its own vaccine chief after industry and media pressure, the FDA signals a shift back toward risk-tolerant biotechnological competition even as top officials defund mRNA research. Whether this moment accelerates acceptance of nucleic-acid platforms or entrenches skepticism will shape seasonal-flu control and pandemic readiness over the next hundred years, when speed of antigen update may matter more than today’s comparator debates.
Perspectives
Left-leaning national and international outlets
PBS, Al Jazeera, The Philadelphia Inquirer, Devdiscourse, Democratic Underground — They present the FDA’s reversal as a victory for science after what they frame as politically motivated anti-vaccine interference by the Trump administration and Health Secretary Robert F. Kennedy Jr. By foregrounding partisan politics, they may over-attribute a routine regulatory dispute to White House hostility, downplaying the FDA’s stated methodological concerns that are documented in the refusal letter.
mRNA-skeptical or right-leaning sources
UPI, Legal Insurrection, matzav.com — They highlight that the FDA initially refused to file because Moderna’s study did not meet ‘best-available standard of care,’ casting the later review as proof the agency is finally applying tougher scrutiny to mRNA shots that may pose extra risks. Echoing Robert F. Kennedy Jr.’s rhetoric, these reports emphasize alleged dangers of mRNA technology and celebrate stricter oversight, potentially overstating unproven safety issues and feeding vaccine hesitancy.
Market-focused business media
The Motley Fool, Healio — They interpret the reversal mainly through an investment and commercial lens, stressing the multibillion-dollar revenue opportunity for Moderna if approval comes by August. Because they cater to investors, their coverage prioritizes stock price movement and profit potential over public-health debates, which can minimize or gloss over lingering safety and regulatory uncertainties.
Like what you're reading?